Erschienen in:
08.09.2020 | Letter to the Editor
Cyproheptadine in the treatment of reversible cerebral vasoconstriction syndrome
verfasst von:
Jennifer Chima, Naresh Mullaguri, Tracey Fan, Pravin George, Christopher R. Newey
Erschienen in:
Acta Neurologica Belgica
|
Ausgabe 6/2021
Einloggen, um Zugang zu erhalten
Excerpt
Reversible cerebral vasoconstriction syndrome (RCVS) is a transient vasculopathy of the cerebral blood vessels often characterized by thunderclap headache and transient cerebral vasoconstriction with ischemic and/or hemorrhagic stroke [
1]. Various risk factors have been described to predispose or trigger RCVS including usage of serotonergic antidepressants, migraine medications, and nasal decongestants [
1,
2]. Apart from removing the precipitating agents, medical management is limited to supportive care, calcium channel blockers, and blood pressure optimization to prevent worsening of vasoconstriction and ischemic complications [
3]. …